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INTRODUCTION
Gastroesophageal reflux disease (GERD) is a chronic condi-
tion that develops when gastric contents flow into the esopha-
gus and cause troublesome symptoms, such as heartburn 
and/or acid regurgitation.1 The severity of GERD does not nec-
essarily indicate actual injury to the esophagus. GERD with-
out reflux esophagitis is more common than erosive esophagi-
tis and is sometimes called non-erosive reflux disease (NERD). 
NERD seems to differ from reflux esophagitis in relation to 
pathophysiology and clinical characteristics; moreover, it is 
known to exhibit a lower response rate to proton pump inhibi-
tors (PPIs) than erosive esophagitis.2 However, recent investi-
gations insisted that responses to PPI in NERD are equal to 
those in erosive gastritis.3
Patients with GERD without reflux esophagitis show vary-
ing characteristics. Savarino, et al.4 sub-classified patients into 
three subtypes based on findings of pH esophageal monitor-
ing: 1) true NERD, with abnormal distal esophageal acid ex-
posure time (AET); 2) hypersensitive esophagus, defined as 
normal distal esophageal AET and positive symptom associa-
tion for either acid and/or non-acid reflux; and 3) functional 
heartburn with normal distal esophageal AET and negative 
symptom association for acid and nonacid reflux.
PPIs are the most effective drugs for the treatment of GERD. 
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enrollment and the prolonged study period. 
Endoscopy and sampling for inflammatory and histologic 
evaluation
The gastroesophageal junction was defined as the most proxi-
mal extent of the gastric folds during endoscopy. Before and 
after treatment, three tissue samples for histologic evaluation 
and three tissue samples for inflammatory biomarker evalua-
tion were obtained from 3 cm above the gastroesophageal 
junction, respectively. Fresh tissues for biomarker evaluation 
were maintained at -80°C until measurement of messenger 
RNA (mRNA). Total mRNA was extracted according to the 
manufacturer’s instructions using TRIzol reagent (Invitrogen 
Life Technologies, Carlsbad, CA, USA). For complementary 
DNA synthesis, total RNA was reverse transcribed using Su-
perScriptTM II (Invitrogen) following the manufacturer’s pro-
tocol. Quantitative polymerase chain reaction (qPCR) was 
performed using iQ SYBR Green Supermix (Applied Biosys-
tems Inc., Carlsbad, CA, USA) and conducted on a Roche Light 
Cycler480 Real-Time PCR System (Idaho Technology Inc., Salt 
Lake City, UT, USA). The target sequences for qPCR were as 
follows: tumor necrosis factor-alpha (TNF-α) (F-5'CAGCC 
TCTTCTCCTTCCTGAT3'; R-5'GCCAGAGGGCTGATTAG 
AGA3'), interleukin 8 (IL-8) (F-5'GCAGCCTTCCTGATTTCTG 
CAGCTC3'; R-5'ACTTCTCCACAACCCTCTGCACCCA3'), in-
terleukin-1 beta (IL-1β) (F-5'CCAGCTACGAATCTCGGAC 
CACC3'; R-5'TTAGGAAGACACAAATTGCATGGTGAAGTCA
GT3'), transient receptor potential vanilloid 1 (TRPV1) (F-
5'GAGTTTCAGGCAGACACTGGAA3'; R-5'CTATCTCGA 
GCACTTGCCTCTCT3'), monocyte chemoattractant protein-1 
(MCP-1) (F-5'GATCTCAGTGCAGAGGCTCG3'; R-5'TGCTTG 
TCCAGGTGGTCCAT3'), glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) (F-5'CCGGGAAACTGTGGCGTGATG 
G3'; R-5'AGGTGGAGGAGTGGGTGTCGCTGTT3'). GAPDH 
was used as an endogenous control, and the Ct value was nor-
malized to GAPDH using the 2-∆∆Ct method. Only reliable 
Many PPIs have been developed and widely used for the man-
agement of acid-related diseases, such as peptic ulcers and 
GERD. PPIs are highly recommended for the management of 
NERD and are thought to provide symptomatic improve-
ment.5 Ilaprazole is the latest PPI and is almost equivalent to 
omeprazole for control of gastric acid secretion.6 It is consid-
ered to improve symptoms. It has a prolonged half-life, com-
pared to other PPIs, and shows powerful dose-dependent in-
hibition of symptoms. Its safety is similar to that of omeprazole.7 
Although a few studies have been published on the efficacy of 
ilaprazole for treatment of acid-related diseases,6,8,9 studies on 
the efficacy of ilaprazole for NERD are lacking.
Herein, we prospectively investigated the efficacy of ilapra-
zole for treatment of patients with heartburn but without re-
flux esophagitis, as assessed by 24-hr combined multichannel 
intraluminal impedance and pH esophageal monitoring (MII-
pH) using standardized histologic criteria and inflammatory 
biomarkers.
MATERIALS AND METHODS
Patients 
Eligible patients included adults who had heartburn lasting for 
more than 6 months and occurring at least twice weekly and 
who were treated at Severance Hospital, Korea between July 
2014 and August 2015. Patients were between the ages of 20 
and 80 years. They showed no erosion at the gastroesophageal 
junction in esophagogastroduodenoscopy. Potential study 
participants were screened and enrolled by a research coordi-
nator. Written informed consent was obtained from each pa-
tient before enrollment. The study protocol was approved by 
the Yonsei University College of Medicine Ethics Committee 
(Institutional Review Board Number: 4-2014-0110) and was 
registered at ClinicalTrials.gov (NCT02666976). 
Study design
This study was undertaken as a single-center, open-label, sin-
gle-arm, prospective study to objectively evaluate the efficacy 
of ilaprazole (Noltec®; IL-YANG Pharmaceutical Co., Ltd., 
Seoul, Korea) for GERD. The study design is shown in Fig. 1. 
The intra-esophageal pressure of all subjects was tested, and 
they underwent MII-pH. The results of MII-pH were used to 
classify patients into three groups: a true NERD group, a hy-
persensitive esophagus group, and functional heartburn 
group. Patients completed GerdQ questionnaires regarding 
their symptoms. They were treated with ilaprazole (20 mg) 
once daily for 4 weeks. After treatment, all subjects completed 
esophagogastroduodenoscopy and the GerdQ questionnaire 
again. Other substances that could influence the relief of 
symptoms related to acid secretion were not permitted during 
the study. We aimed to enroll 37 patients; however, the study 
was concluded prematurely owing to the difficulty of subject 
Eligible patients 
(n=28)
Inclusion criteria
   • 20≤age≤80
   •  Heartburn at least twice 
a week
   •  No erosion at EGJ
Drop out
   • Refusal of patients (n=7)
   •  Eosinophilic esophagitis 
(n=1)Finally enrolled patients 
(n=20)
True NERD (n=2) Hypersensitive esophagus (n=10)
Functional 
heartburn (n=8)
Ilaprazole 20 mg qd 4 weeks
Fig. 1. Study design. NERD, non-erosive reflux disease; EGJ, esophago-
gastric junction.
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quantitative real-time PCR (qRT-PCR) data points were used 
for analysis. 
Histopathologic evaluation
Histologic findings included basal cell hyperplasia, papillary 
elongation, dilated intercellular spaces (DIS), intraepithelial 
eosinophils, and intraepithelial T lymphocytes. All specimens 
were assessed by a single histologist (H.K.). To classify the sever-
ity of the histologic findings, we used the histologic criteria and 
severity score (score range, 0–2) set by the Esohisto project.10,11
Manometric study
We used an eight-channel, water-perfused esophageal manom-
etry catheter (MUI Scientific Company, Mississauga, ON, Can-
ada) and a water-perfused, low-compliance perfusion system 
(Synetics Medical Co., Stockholm, Sweden). The manometric 
analysis was performed before the MII-pH study. During the 
esophageal manometry study, we evaluated variable parame-
ters, such as the resting lower esophageal sphincter (LES) pres-
sure, the length of LES, the amplitude of pressure waves, and the 
duration of pressure waves.
24-hr combined multichannel intraluminal impedance and 
pH esophageal monitoring
MII-pH was performed before treatment using an ambulatory 
multichannel intraluminal impedance and pH monitoring 
system (Sleuth; Sandhill Scientific, Inc., Highland Ranch, CO, 
USA). The DeMeester score, distal esophageal AET, total number 
of reflux episodes, symptom association probability (SAP), and 
the symptom index (SI) were determined. The distal esophageal 
AET was defined as the total time with a pH <4, divided by the 
total monitoring time. A percent time <4.2% with pH <4 over 24 
hours was referred to as normal. Pathologic acid reflux was de-
fined as a distal esophageal acid exposure percent time >4.2%.4
The SAP was calculated for acid and nonacid reflux using a 
custom-made Excel macro function. The SAP was considered 
to be positive at ≥95%.12 The SI was calculated using the Bioview 
analysis software (Sandhill Scientific, Inc.). It was defined as 
the number of symptoms associated with reflux divided by 
the total number of symptoms. The SI was considered to be 
positive when ≥50%.13 We defined a positive symptom associa-
tion for reflux as either a positive SAP or a positive SI. 
Outcome measures
Our aim was to demonstrate the efficacy of ilaprazole for GERD 
without reflux esophagitis. To assess the improvement of symp-
toms, all patients completed the GerdQ questionnaire before 
and after taking ilaprazole. The questionnaire is composed of 
six items and can be used as a diagnostic tool for GERD. It has 
also been used as a tool for evaluating PPI responses in GERD 
patients.14 We classified 20 patients as either those in whom 
GERD was well-controlled with PPI therapy (responders) or 
those in whom it was not well-controlled with PPI therapy (par-
tial responders). Responders were defined as patients who re-
ported 0 days of having heartburn (question 1), regurgitation 
(question 2), sleep disturbance (question 5), or over-the-coun-
ter acid suppressive medication use (question 6) during the 
preceding week. We defined partial responsiveness in PPI us-
ers as more than 1 day of experiencing any one of heartburn, 
regurgitation, sleep disturbances, and additional medications, 
as reported in the GerdQ.15 Our secondary endpoint included 
changes in histological findings and inflammatory biomark-
ers on tissue analysis after treatment. 
Statistical analysis 
Calculations were performed using SPSS statistical software, 
version 18.0 (SPSS Inc., Chicago, IL, USA). Continuous vari-
ables are presented as means±standard deviation, and dis-
crete variables are expressed as numbers and percentages. 
The baseline characteristics of the patients in the three groups 
were compared using the chi-squared test or Fisher’s exact test, 
one-way ANOVA, and the Kruskal-Wallis test. Paired compar-
isons of parameters before and after taking ilaprazole were 
performed using a paired t-test or a Wilcoxon signed-rank test. 
Results are presented as odds ratios, 95% confidence intervals, 
and p values. p≤0.05 was considered statistically significant. 
Using a significance level of 5% and a statistical power of 90% 
with a two-sided test, a sample size of 37 patients was required 
for our treatment group, assuming a 30% drop-out rate. 
RESULTS
The patient’s characteristics and marker of histology 
and inflammation before treatment
Twenty-eight individuals participated in our study. Of these 
subjects, 8 patients were excluded from the study; 7 patients 
discontinued due to improvement of symptoms or unexpect-
ed patient refusal, and 1 patient was diagnosed with eosino-
philic esophagitis based on their histological results (Fig. 1). 
The mean age of the 20 patients was 59.5±9.4 years, and the 
patients included 16 females and 4 males (80% and 20%, re-
spectively; ratio=4:1). All 20 patients had previous history of PPI 
use, and 14 patients (70%) responded to PPI. The mean GerdQ 
score before treatment was 11.1±2.1. Thirteen patients (65%) 
had a GerdQ score of 8 or more at baseline. There were eight 
responders and 12 partial responders after taking ilaprazole. 
The baseline clinical characteristics and parameters of MII-
pH are presented in Table 1. Eight patients (40%) were classi-
fied as having functional heartburn. The remaining patients 
were defined with true NERD (n=2, 10%) and a hypersensitive 
esophagus (n=10, 50%). The hypersensitive esophagus group 
comprised five with an acid-sensitive esophagus and five with 
a weak acid-sensitive esophagus. The proportion of patients 
with a GerdQ score 8 or more was significantly higher in the 
true NERD (100%) and hypersensitive esophagus (70%) groups, 
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compared to functional heartburn group (50%) (p<0.001). 
Among the findings of MII-pH analysis, baseline AET was sig-
nificantly higher in patients with true NERD than those with 
hypertensive esophagus and functional heartburn (p<0.001). No 
differences in manometric parameters were observed among 
subtypes. 
No differences in TNF-α, IL-8, IL-1β, TRPV1, and MCP-1 
among subtypes (Table 2). Among the pre-treatment histologi-
cal findings, there was no difference among the subgroups, ex-
cept in infiltration of intraepithelial T lymphocytes, which was 
higher in the hypersensitive esophagus group than in the func-
tional heartburn group (p=0.03). The DIS and infiltration of in-
traepithelial eosinophils were more clustered to scores 0 to 1, 
compared to other histologic findings. 
Efficacy of ilaprazole on GerdQ, histology, and 
inflammatory cytokines
The histopathologic findings revealed decreases in scores for 
all parameters after ilaprazole treatment. Some findings, such 
as basal cell hyperplasia, papillary elongation, and infiltration 
of intraepithelial T lymphocytes, were improved significantly 
(p=0.008, p=0.021, p=0.008; respectively) (Fig. 2). Improve-
ment of basal cell hyperplasia, papillary elongation, and infil-
tration of intraepithelial T lymphocytes were clearly demon-
strated with hematoxylin and eosin (H&E) staining (Fig. 3).
When we analyzed three histologic findings between reflux-
related subtype (true NERD+hypersensitive esophagus group) 
and functional heartburn, the degrees of basal cell hyperpla-
sia, papillary elongation, and infiltration of intraepithelial T 
Table 1. The Baseline Characteristics and Results of MII-pH 
Characteristics True NERD Hypersensitive esophagus Functional heartburn Total p value
Mean age (yr) 69.0±12.7 59.2±10.7 57.4±6.1 59.5±9.4 0.307
Male (%) 1 (50.0) 2 (20.0) 1 (12.5) 4 (20.0) 0.740
GerdQ score 11.0±1.4 11.1±1.9 11.1±2.6 11.1±2.1 0.997
GerdQ≥8 2/2 7/10 4/8 13/20 <0.001
Responder/partial responder 0/2 5/5 3/5 8/12 0.413
MII-pH parameters
Acid exposure time (%) 10.0±4.5 1.1±1.2 0.5±0.7 1.7±3.2 <0.001
Total number of reflux episodes 49.0±46.2 32.0±15.3 42.4±33.7 37.8±26.1 0.601
Acid reflux (%) 37.5±34.6 14.9±12.1 13.3±8.3 16.5±14.5 0.088
Length of abdominal LES (cm) 3.5±2.1 3.4±1.0 2.4±0.7 3.0±1.1 0.100
LES pressure (mm Hg) 19.4±4.7 14.5±5.0 13.0±2.7 14.4±4.4 0.196
Amplitude pressure waves (mm Hg) 98.4±42.3 70.6±21.7 70.6±20.9 73.4±23.5 0.299
Duration pressure waves (sec) 4.1±0.2 3.4±0.6 3.5±0.3 3.5±0.5 0.208
NERD, non-erosive reflux disease; MII-pH, multichannel intraluminal impedance and pH esophageal monitoring; LES, lower esophageal sphincter. 
Table 2. Inflammatory and Histologic Findings at Baseline 
Parameters True NERD Hypersensitive esophagus Functional heartburn Total p value
Inflammatory markers
TNF-α* 0.66±0. 61 0.24±4.77 3.53±4.39 2.61±4.39  0.742
IL-8* 2.50±0.40  4.45±6.94   6.73±11.09   5.09±8.19  0.783
IL-1β* 0.27±0.15  0.34±0.12   0.38±0.23   0.35±0.17  0.724
TRPV1* 0.24±0.14  0.63±0.89   1.02±0.90   0.74±0.85  0.475
MCP-1* 9.19±3.17  15.09±9.70 19.62±12.88  16.00±10.55 0.477
Histologic markers (score/number)†
Basal cell hyperplasia 2/2 9/10 10/8 0.656
Papillary elongation 2/2 8/10 6/8 0.098
DIS 0/2 19/10 4/8 0.391
Eosinophils 0/2 10/10 0/10 0.348
T lymphocytes 3/2 14/10 9/10 0.030
NERD, non-erosive reflux disease; TNF-α, tumor necrosis factor-alpha; IL-8, interleukin 8; IL-1β, interleukin-1 beta; TRPV1, transient receptor potential vanilloid 1; 
MCP-1, monocyte chemoattractant protein-1; qRT-PCR, quantitative real time polymerase chain reaction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; DIS, 
dilated intercellular spaces.
*TNF-α, IL-8, IL-1β, TRPV1, and MCP-1 were measured by qRT-PCR. GAPDH was used as the endogenous control. The Ct values of TNF-α, IL-8, TRPV1, and MCP-1 
were normalized to GAPDH using the 2-∆∆Ct method. Fold-change in TNF-α, IL-8, TRPV1, and MCP-1 compared to GAPDH was amplified by 104-fold for conve-
nience. Some samples were not sufficient to perform qRT-PCR, and only reliable qRT-PCR data points were used for analysis (TNF-α: 16; IL-8: 18; IL-1β: 19; TRPV1: 
18; MCP-1:14). †Histologic marker represented as the sum of score/number of patients in each subgroup. Histologic findings include basal cell hyperplasia, papil-
lary elongation, DIS, intraepithelial eosinophils, and intraepithelial T lymphocytes.
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lymphocytes were reduced significantly in reflux-related sub-
type (p=0.034, p=0.023, and p=0.034, respectively) (Fig. 4). In 
patients with heartburn, none of the three findings showed any 
difference before and after treatment. Next, we analyzed the 
histologic responses between patients with GerdQ ≥8 and 
GerdQ <8 (Fig. 5). Similarly, the degrees of basal cell hyper-
plasia and papillary elongation were reduced significantly pa-
tients with GerdQ ≥8 (p=0.043, and p=0.048; respectively). 
Among the inflammatory cytokines examined, expression 
of TNF-α (p=0.049), IL-8 (p=0.046), TRPV1 (p=0.045), and 
MCP1 (p=0.042) were decreased significantly after treatment 
with ilaprazole (Fig. 6). However, IL-1β did not change after 
treatment. 
After treatment, the patients’ GerdQ scores were signifi-
cantly reduced (11.1±2.1 and 3.2±3.0, p<0.001). There were 
eight responders (44%) and 12 partial responders. There was 
no difference in the proportion of respondents according to 
the subtype of GerdQ score and MII-pH results. 
DISCUSSION
This is the first prospective study to show the effect of ilapra-
zole on patients with GERD without reflux esophagitis, using 
not only subjective measures, such as GerdQ scores, but also 
objective methods, including standardized histologic param-
eters and inflammatory markers. Ilaprazole significantly im-
proved histologic findings, including basal cell hyperplasia, 
papillary elongation, and infiltration of intraepithelial T lympho-
cytes. This histologic improvement was specifically observed 
only in reflux-subtypes, compared to functional heartburn. 
We attempted to measure symptoms objectively, using the 
GerdQ questionnaire as a symptom rating scale. A GerdQ score 
of 8 has been determined to be an appropriate cutoff value in a 
Japanese population.16 In this study, 65% of patients showed 
GerdQ ≥8. After treatment with ilaprazole, 18 of 20 patients 
showed a GerdQ score <8. Among them, 12 patients were clas-
sified as partial responders. Considering that the number of 
individuals with functional heartburn was not small in this 
study, the response rate to ilaprazole is relatively high. We hy-
pothesize that the patients in the functional heartburn group 
might have been primarily composed of PPI responders in this 
study; this could have induced the high rate of responses to il-
aprazole observed among the functional heartburn group in 
our study. 
In our study, we adapted the MII-pH to subdivide the patients 
into three groups. The proportion of patients with true NERD/
hypersensitive esophagus/functional heartburn was 10%/ 
50%/40%. The ratio of patients with functional heartburn cor-
related well with a previous report, although the number of pa-
tients with true NERD was somewhat lower than in previous 
studies.17-19
Recently, microscopic changes in GERD have received at-
tention as diagnostic and monitoring tools. Pathologic reflux 
in the esophagus results in injury to epithelial cells of the mu-
cosa. It can lead to promotion of cell turnover and basal cell 
hyperplasia. Hyperemia of the capillaries presents as papillary 
elongation.20 Infiltration of lymphocytes appears to be more 
frequent than infiltration with eosinophilic or neutrophilic gran-
ulocytes.21 A previous study showed significant histopatho-
logical differences between NERD and functional heartburn.22 
According to our data, only infiltration of intraepithelial T cells 
differed between the two. This discrepancy with previous re-
ports might be caused by the small sample size, as we could 
only include two cases of true NERD in this study. We tried to 
resolve this issue over the course of the study, but had difficulty 
in enrolling patients and eventually had to terminate it early. 
Basal cell hyperplasia, papillary elongation, and infiltration 
of T lymphocytes were improved after treatment in all patients 
in this study. All of these histologic markers have been recog-
nized as evidence of reflux disease.23 As studied earlier, wheth-
er histologic changes revert to normal can be used to judge the 
efficacy of PPIs, such as esomezole.24 Ilaprazole also improved 
these microscopic findings in the present study. Herein, we 
found that histologic improvement is generally seen only in 
patients with a reflux subtype or GERD ≥8 score. These results 
show that ilaprazole is involved in the pathophysiologic process 
by reflux.
Among histologic changes, DIS is known as an early marker 
of tissue injury in GERD and NERD.25 A previous study dem-
onstrated that DIS is well correlated with AET of the distal 
esophagus in NERD and that patients with abnormal AET are 
more likely to show DIS than those with normal AET.26 In our 
study, DIS did not change after ilaprazole. These results sug-
gest that DIS is a good indicator of acid reflux, although our 
study included too few patients with true NERD, suggesting 
Fig. 2. Histologic findings before and after treatment: basal cell hyper-
plasia (p=0.008); papillary elongation (p=0.021); DIS (p=0.391); infiltration 
of intraepithelial eosinophils (p=0.348); infiltration of intraepithelial T lym-
phocytes (p=0.008). *p<0.05, †p<0.01. DIS, dilated intercellular spaces; eo-
sinophils, infiltration of intraepithelial eosinophils; T lymphocytes, infiltra-
tion of intraepithelial T lymphocytes.
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that its impact was markedly reduced. In fact, the basal score 
of DIS and infiltration of eosinophil were almost clustered to 
scores of 0 to 1 before treatment. For this reason, DIS and in-
filtration of eosinophil were not good indicators of treatment 
responses in our study. In this study, DIS was measured by 
H&E staining, not by electron microscopy. This fact may be a 
factor in reducing the importance of DIS.
Recent studies have demonstrated that some immune mech-
A
C
E
B
D
F
Fig. 3. Representative cases showing changes in histologic findings after treatment with ilaprazole. Several histologic findings showed improvement 
following treatment. The thickness of the basal layer changed from 40% (H&E, ×100) (A) to 10% (H&E, ×100) (B). The length of papillae changed from 
80% (H&E, ×100) (C) to 40% (H&E, ×100) (D) of the total epithelial thickness. Infiltration of T lymphocytes changed from 16/high power field (H&E, ×200) 
(E) to 4/high power field (H&E, ×200) (F). H&E, hematoxylin and eosin.
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by treatment with PPIs, such as lansoprazole.31-33 In our study, 
all inflammatory biomarkers except IL-1β decreased after tak-
ing ilaprazole, with moderate amplitudes.
This study has some limitations. First, the number of sub-
jects was small because the study was ended due to poor en-
rollment. However, the subgroup proportions were similar to 
those reported in studies of large populations. This means 
there will be less bias, even though the number of patients with 
true NERD was only two. Second, we had no control group. To 
improve confidence, a comparison study between the efficacy 
of ilaprazole and that of other PPIs is required. Third, we did 
not consider the placebo effect of ilaprazole itself in our re-
sults. Ilaprazole is expected to show a placebo effect on symp-
tomatic responses, similar to other PPIs.34 To complement 
these facts, we introduced a highly objective method, includ-
ing histological exams and use of biomarkers, in order to ex-
clude a possible placebo effect. Fourth, we only had a single 
pathologist interpret the histologic findings.
Despite these limitations, we showed that ilaprazole is ef-
anisms are mediated by specific cytokines or chemokines in 
GERD.27 IL-8 is a neutrophil chemotactic factor that plays a 
crucial role in inducing inflammation and is a representative 
chemokine in the pathogenesis of NERD.28 IL-1β also appears 
to play an important role therein, including inflammation and 
fibrosis, and is known to be related to NERD.29 TNF-α induced 
transcription of oncogenes, such as c-myc, and its epithelial ex-
pression was increased in the progress of Barrett’s esophagus 
to adenocarcinoma. IL-1β and TNF-α may be related to the 
Barrett’s esophagus-dysplasia-carcinoma sequence.27 MCP-1 
attracts monocytes and lymphocytes and was higher in pa-
tients with reflux esophagitis than healthy controls.27
TRPV1 has been implicated in the mechanism of acid-in-
duced inflammation in GERD.30 These markers were tested 
for use as tools in determining the efficacy of drugs in treating 
NERD. The expression of IL-8, IL-1β, and MCP-1 was decreased 
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Fig. 4. Histologic responses between reflux-related subtype (true NERD+ 
hypersensitivity group) and proton pump inhibitor-responsive functional 
heartburn groups. The degrees of basal cell hyperplasia (p=0.034), papil-
lary elongation (p=0.023), and infiltration of intraepithelial T lymphocytes 
(p=0.034) were reduced significantly in the reflux-related group. *p<0.05. 
T lymphocytes, infiltration of intraepithelial T lymphocytes. NERD, non-
erosive reflux disease; HE, hypersensitive esophagus.
Fig. 6. Inflammatory biomarkers before and after treatment. (A) TNF-α, (B) 
IL-8, (C) IL-1β, (D) TRPV1, and (E) MCP-1 were measured by qRT-PCR. GAP-
DH was used as the endogenous control. The Ct values of TNF-α, IL-8, 
TRPV1, and MCP-1 were normalized to GAPDH using the 2-∆∆Ct method. 
Some samples were not sufficient to perform qRT-PCR, and only reliable 
qRT-PCR data points were used for analysis (TNF-α: 16; IL-8: 18; IL-1β: 19; 
TRPV1: 18; MCP-1: 14). *p<0.05. TNF-α, tumor necrosis factor-alpha; IL-8, 
interleukin 8; IL-1β, interleukin-1 beta; TRPV1, transient receptor potential 
vanilloid 1; MCP-1, monocyte chemoattractant protein-1; qRT-PCR, quanti-
tative real time polymerase chain reaction; GAPDH, glyceraldehyde 3-phos-
phate dehydrogenase.
Fig. 5. Histologic responses between patients with GerdQ ≥8 and GerdQ 
<8. The degrees of basal cell hyperplasia (p=0.043) and papillary elon-
gation (p=0.048) were reduced significantly patients with GerdQ ≥8. The 
papillary elongation was reduced significantly in patients with GerdQ 
<8 (p=0.038). *p<0.05. T lymphocytes, infiltration of intraepithelial T lym-
phocytes.
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fective in treatment of GERD patients without esophagitis in 
terms of symptoms, histology, and inflammation. Further study 
with a larger number of patients with NERD, however, is need-
ed to validate our findings.
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